ID   LXF 2478L
AC   CVCL_E6EL
SY   LXFE 2478
RX   DOI=10.1158/1535-7163.TARG-19-LB-B05;
RX   PubMed=29748209;
RX   PubMed=31467113;
CC   Characteristics: Established from a patient-derived xenograft established in nude mice (DOI=10.1158/1535-7163.TARG-19-LB-B05).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Val769_Asp770insAlaSerVal (c.2308_2309insCCAGCGTGG) (c.2300_2308dup) (M766_A767insASV) (p.Ala767_Val769dupAlaSerVal) (A767_V769dupASV); ClinVar=VCV000177678; Zygosity=Heterozygous (DOI=10.1158/1535-7163.TARG-19-LB-B05).
CC   Donor information: Established from a patient whose tumor was resistant to erlotinib (DOI=10.1158/1535-7163.TARG-19-LB-B05).
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
DI   NCIt; C9133; Lung adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   DOI=10.1158/1535-7163.TARG-19-LB-B05;
RA   Kelter G., Peille A.-L., Fehr J., Klett H., Maier A., Posch M.,
RA   Metz T.M.;
RT   "Characterization of a panel of 79 PDX-derived cell lines with a focus
RT   on the EGFR exon 20 insertion mutation-driven NSCLC model LXFE 2478.";
RL   Mol. Cancer Ther. 18 Suppl. 12:LBB05-LBB05(2019).
//
RX   PubMed=29748209; DOI=10.1158/1535-7163.MCT-17-1206;
RA   Hasako S., Terasaka M., Abe N., Uno T., Ohsawa H., Hashimoto A.,
RA   Fujita R., Tanaka K., Okayama T., Wadhwa R., Miyadera K., Aoyagi Y.,
RA   Yonekura K., Matsuo K.;
RT   "TAS6417, a novel EGFR inhibitor targeting exon 20 insertion
RT   mutations.";
RL   Mol. Cancer Ther. 17:1648-1658(2018).
//
RX   PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223;
RA   Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M.,
RA   Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A.,
RA   Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B.,
RA   Kobayashi S.S.;
RT   "TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase
RT   inhibitor with a broad spectrum of preclinical activity against
RT   clinically relevant EGFR mutations.";
RL   Mol. Cancer Res. 17:2233-2243(2019).
//